FTC Narrowly Approves Mylan-Upjohn Merger As Dissenters Call For Change
Settlement Seeks To Address Concerns In Ten Markets
Mylan’s proposed $12bn combination with Pfizer’s Upjohn unit is expected to close next month following a settlement agreement with the FTC, with a requirement to address competition concerns in ten markets. The FTC was however strongly divided on the deal, with dissenters labelling the directives of the Commission as “deeply flawed, favoring routine over rigor.”
